Fig. 3From: Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitorsFrequency of p.T790M acquisition. Frequency of total p.T790M acquisition in patients under reversible (a) and irreversible (b) EGFR TKI therapy for > 6 months, respectively. Chi Square statistics identified a significant difference in the prevalence of p.T790M mutation in reversible vs irreversible EGF TKI treated patients (p = 0.019)Back to article page